Abstract
The aim of this study is to investigate the course of magnetic resonance imaging (MRI) signs of inflammatory and destructive changes in rheumatoid arthritis (RA) wrist and metacarpophalangeal (MCP) joints during etanercept treatment. MRI of the non-dominant wrist and second to fifth MCP joints was performed in five clinical active RA patients before and 4 and 16 weeks after initiation of etanercept treatment. MRI was evaluated according to the EULAR–OMERACT RA MRI reference image atlas. The median 28-joint count disease activity score (DAS28; erythrocyte sedimentation rate based) was 5.6 (range 5.0–6.8) at baseline and 3.5 (1.5–4.1) at week 16 (decreased in all patients compared to baseline, Wilcoxon–Pratt, p < 0.05). The median MRI synovitis score was 18 (14–21), 18 (10–20) and 16 (10–20) at baseline, week 4 and 16, respectively (decreased in all patients compared to baseline, Wilcoxon–Pratt, p < 0.05), while corresponding MRI bone oedema scores were 4 (0–13), 3 (0–9) and 1 (0–3; NS). The median MRI bone erosion score was 27 (11–111; NS) at all time points. Four patients had identical total bone erosion scores at baseline and week 16, whereas one patient showed a reduced score. In conclusion, one patient showed erosive regression, while no patient showed erosive progression on MRI during 16 weeks of etanercept therapy; even though clinical and MRI signs of joint inflammation remained. This small study supports that erosive progression judged by MRI is minimal in RA patients treated with etanercept, even in joints with persistent inflammation.
Similar content being viewed by others
References
Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin ME, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410):675–681, February 28
Lipsky PE, van der Heijde DMFM, StClair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldman M, Harriman GR, Maini RN (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343:1594–1602
McQueen FM, Stewart N, Crabbe J, Robinson E, Yeoman S, Tan PL, McLean L (1999) Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals progression of erosions despite clinical improvement. Ann Rheum Dis 58(3):156–163, March
Conaghan PG, O’Connor P, McGonagle D, Astin P, Wakefield RJ, Gibbon WW, Quinn M, Karim Z, Green MJ, Proudman S, Isaacs J, Emery P (2003) Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis Rheum 48(1):64–71, January
Ejbjerg BJ, Vestergaard A, Jacobsen S, Thomsen HS, Østergaard M (2005) The smallest detectable difference and sensitivity to change of magnetic resonance imaging and radiographic scoring of structural joint damage in rheumatoid arthritis finger, wrist, and toe joints: a comparison of the OMERACT rheumatoid arthritis magnetic resonance imaging score applied to different joint combinations and the Sharp/van der Heijde radiographic score. Arthritis Rheum 52(8):2300–2306, August
McQueen FM, Stewart N, Crabbe J, Robinson E, Yeoman S, Tan PL, McLean L (1998) Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis 57(6):350–356, June
Lindegaard HM, Vallø J, Hørslev-Petersen K, Junker P, Østergaard M (2006) Low-cost, low-field dedicated extremity magnetic resonance imaging in early rheumatoid arthritis: a 1-year follow-up study. Ann Rheum Dis 65(9):1208–1212, September 1
Østergaard M, Edmonds J, McQueen F, Peterfy C, Lassere M, Ejbjerg B, Bird P, Emery P, Genant H, Conaghan P (2005) The EULAR–OMERACT rheumatoid arthritis MRI reference image atlas. Ann Rheum Dis 64(Suppl 1):i2–i55, February
van Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, Freundlich B, Macpeek D (2006) Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis 65(11):1478–1483, February 7
Sharp JT, Young DY, Bluhm GB, Brook A, Brower AC, Corbett M, Decker JL, Genant HK, Gofton JP, Goodman N, Larsen A, Lidsky MD, Pussila P, Weinstein AS, Weissman BN (1985) How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 28:1326–1335
Østergaard M, Hansen M, Stoltenberg M, Jensen KE, Szkudlarek M, Pedersen-Zbinden B, Lorenzen I (2003) New radiographic bone erosions in the wrists of patients with rheumatoid arthritis are detectable with magnetic resonance imaging a median of two years earlier. Arthritis Rheum 48(8):2128–2131, August
Perry D, Stewart N, Benton N, Robinson E, Yeoman S, Crabbe J, McQueen F (2005) Detection of erosions in the rheumatoid hand: a comparative study of multidetector computerized tomography versus magnetic resonance scanning. J Rheumatol 32(2):256–267, February
Døhn UM, Ejbjerg B, Court-Payen M, Hasselquist M, Narvestad E, Szkudlarek M, Møller JM, Thomsen H, Østergaard M (2006) Are bone erosions detected by magnetic resonance imaging and ultrasonography true erosions? A comparison with computed tomography in rheumatoid arthritis metacarpophalangeal joints. Arthritis Res Ther 8(4):R110
Quinn MA, Conaghan PG, O’connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P (2005) Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52(1):27–35, January
Østergaard M, Duer A, Nielsen H, Johansen JS, Narvestad E, Ejbjerg BJ, Baslund B, Møller JM, Thomsen HS, Petersen J (2005) Magnetic resonance imaging for accelerated assessment of drug effect and prediction of subsequent radiographic progression in rheumatoid arthritis: a study of patients receiving combined anakinra and methotrexate treatment. Ann Rheum Dis 64(10):1503–1506, October
Acknowledgements
Grant support by: Wyeth Pharmaceuticals
Contrast agent: GE Healthcare Amersham, UK
Illustrations by: Ms. Susanne Østergaard and Ms. Dorthe Dyrlund
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Døhn, U.M., Skjødt, H., Hetland, M.L. et al. No erosive progression revealed by MRI in rheumatoid arthritis patients treated with etanercept, even in patients with persistent MRI and clinical signs of joint inflammation. Clin Rheumatol 26, 1857–1861 (2007). https://doi.org/10.1007/s10067-007-0589-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-007-0589-y